RA CAPITAL MANAGEMENT, L.P.
Q1 2020 13F-HR Holdings
Net value change ($000)
-131,985
(-4.0%)
New positions
18
Sold out positions
4
Turnover %
42.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2019
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ALEC | 82,363 | 478.0% |
| KALA | 78,845 | 470.9% |
| EXEL | 77,920 | NEW |
| AXSM | 74,001 | 194.7% |
| ADVM | 71,054 | NEW |
| BDTX | 64,618 | NEW |
| VSTM | 49,116 | NEW |
| ChemoCentryx, Inc. | 41,292 | 32.6% |
| GILD | 40,968 | NEW |
| MOMENTA PHARMACEUTICALS INC | 40,329 | 141.4% |
Top Reduces (Value $000, Stocks/ETFs)
| Synthorx, Inc. | -679,652 | -100.0% |
| Forty Seven, Inc. | -76,112 | -100.0% |
| Audentes Therapeutics, Inc. | -53,999 | -100.0% |
| RYTM | -41,968 | -33.7% |
| Orchard Therapeutics plc | -30,813 | -35.1% |
| ASND | -28,792 | -4.9% |
| CRNX | -18,219 | -38.7% |
| Eidos Therapeutics, Inc. | -18,167 | -14.6% |
| PHAT | -17,837 | -15.7% |
| Prevail Therapeutics Inc. | -13,744 | -25.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|